mRNA COVID-19 vaccines induce superior immunoglobulin A titers in patients with cancer compared with viral vector vaccines: implications for immunization strategies
Objectives: Immunoglobulin (Ig) A antibodies are involved in mucosal immunity and eliminate pathogens immediately at the point of entry. Vaccine-induced IgA antibodies could contribute to an additional layer of protection against SARS-CoV-2 for infection-prone patients with cancer. This might be par...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-09-01
|
| Series: | International Journal of Infectious Diseases |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1201971225001638 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Objectives: Immunoglobulin (Ig) A antibodies are involved in mucosal immunity and eliminate pathogens immediately at the point of entry. Vaccine-induced IgA antibodies could contribute to an additional layer of protection against SARS-CoV-2 for infection-prone patients with cancer. This might be particularly relevant for patients with cancer because they mount reduced IgG antibody titers after dual-dose BNT162b2 COVID-19 vaccination and even lower responses after double-dose ChAdOx1 vaccination than healthy individuals. However, data on vaccine-induced IgA antibodies are scarce, especially in patients with cancer. Methods: This study compares SARS-CoV-2 anti-spike (S1) IgA antibodies after dual-dose BNT162b2 vs ChAdOx1 vaccination in patients with cancer. SARS-CoV-2 anti-S1 IgA antibodies were quantified in serum samples collected 7 days after the second vaccination dose (N = 213) (IEQ-CoVS1RBD-IgA-1-RB enzyme-linked immunosorbent assay kit, RayBiotech) and analyzed with colorimetric detection. In addition, correlations with different aspects of humoral immunity were assessed (neutralizing and IgG antibodies). Results: Significantly lower anti-S1 IgA antibody titers were reported in patients with cancer after dual-dose ChAdOx1 than BNT162b2 vaccination. Moreover, patients with cancer who received dual-dose BNT162b2 vaccination had a significant 16.44-fold increased chance to mount detectable IgA antibodies compared with patients receiving ChAdOx1 vaccination. Conclusions: These findings highlight the potential role of boosters or alternative strategies to sustain mucosal immunity. |
|---|---|
| ISSN: | 1201-9712 |